All Posts Tagged With: "PFE"
(QGEN) Qiagen Expands with New Deals
In an attempt to expand its companion diagnostic portfolio for several types of new anti-cancer drugs, Qiagen (QGEN) recently entered into two different agreements with US biotech companies, namely Insight Genetics, Inc. and Personal Genome Diagnostics Inc. Through the agreement,...
13Jan2012 | vitalstocks | 0 comments | Continued(JNJ) Pharma & Biotech Stock Review & Outlook – Industry Outlook
With 2011 coming to an end, the pharmaceutical industry continues to face challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and limited late-stage catalysts. The next five years are expected to reflect a significant...
29Dec2011 | vitalstocks | 0 comments | Continued(NVS) Novartis’ Cancer Drug Afinitor Shows Promise for Breast Cancer
Novartis’ (NVS) cancer drug Afinitor took a significant step forward, as the company once again presented encouraging data from late-stage trials of Afinitor for the treatment of breast cancer, an indication for which management estimates sales potential in excess of $1 billion....
12Dec2011 | vitalstocks | 0 comments | Continued(EU) Emerging Markets: The Way Forward
According to Irish orator, philosopher, & politician Edmund Burke, change is the most powerful law of nature. The winds of change seem to be sweeping across the pharmaceutical industry as well. Until recently, most commercialization efforts were focused on the U.S. —...
7Dec2011 | vitalstocks | 0 comments | Continued(PFE) Watson Pharmaceuticals Joins Pfizer for Generic Lipitor
November 30, 2011 was a big day for Pfizer, Inc. (PFE) with its blockbuster cholesterol drug, Lipitor, losing exclusivity in the US. With so many drugs losing exclusivity, why is the loss of exclusivity of Lipitor such a major event? Well, Lipitor has been a huge revenue generator...
6Dec2011 | vitalstocks | 0 comments | Continued(MYL) Mylan Earns FDA Approval
Generic maker, Mylan Inc. (MYL) recently announced that its Indian subsidiary Mylan Laboratories has received tentative approval from the US Food & Drug Administration (FDA) for a fixed-dose combination of generic versions of Bristol Myers Squibb’s (BMY) drug Reyataz and...
5Dec2011 | vitalstocks | 0 comments | Continued(MYL) Mylan Settles with Novartis
Mylan, Inc. (MYL) recently announced a settlement agreement with Novartis (NVS) relating to the generic version of Novartis’ bioidentical estrogen therapy Vivelle-Dot. As a result of the resolution, the lawsuit filed by Novartis will be dismissed and Mylan can launch a generic...
28Nov2011 | vitalstocks | 0 comments | Continued(EU) Pharmaceuticals Stock Outlook – September 2011 – Industry Outlook
The pharmaceutical industry continues to be impacted by major issues such as sluggish prescription trends, European Union (EU) pricing pressure, intensifying generic competition and limited late-stage catalysts. The next five years are expected to witness a significant imbalance...
23Sep2011 | vitalstocks | 0 comments | Continued(AZN) AstraZeneca Coverage Initiated at Neutral
We are initiating coverage on AstraZeneca (AZN) with a Neutral recommendation and a target price of $47.00. AstraZeneca, headquartered in London, UK, is one of the largest biopharmaceutical companies in the world. AstraZeneca’s business can be broken down into separate lines...
21Sep2011 | vitalstocks | 0 comments | Continued(NVS) Novartis Drug Cleared in European Union for SEGA
Novartis (NVS) recently received a boost when its drug Votubia was approved for the treatment of subependymal giant cell astrocytomas (SEGA), a benign brain tumor associated with tuberous sclerosis (TS) in the European Union (EU). For the first time ever will such a medication...
20Sep2011 | vitalstocks | 0 comments | Continued(VVUS) Vivus’ Erectile Dysfunction Drug Presents Positive Data
Vivus Inc. (VVUS) recently presented positive data from a late-stage trial on its erectile dysfunction (ED) candidate, avanafil, at the 47th European Association for the Study of Diabetes Annual Meeting. The REVIEW-Diabetes study (TA-302), which enrolled 390 patients with type...
20Sep2011 | vitalstocks | 0 comments | Continued(ENZN) Enzon Pharmaceuticals Analyst Downgrades Shares to Sell
We recently downgraded our rating on Enzon Pharmaceuticals Inc. (ENZN) from Neutral to Underperform with a target price of $9.50. In mid-May 2011, Enzon announced plans to halt the development of its lead pipeline compound PEG-SN38 (EZN-2208), a PEGylated version of the active...
15Sep2011 | vitalstocks | 0 comments | Continued(BMY) Bristol-Myers Squibb and Pfizer Get Encouraging Data
Recently, Bristol-Myers Squibb Company (BMY) and partner Pfizer (PFE) announced encouraging data from a late-stage study (ARISTOTLE: n=18,201) which evaluated their blood thinner Eliquis (apixaban) in patients suffering from erratic heartbeat and carrying at least one additional...
14Sep2011 | vitalstocks | 0 comments | Continued(NVS) Novartis Neuroendocrine Tumors Drug Cleared in European Union
Novartis’(NVS) drug Afinitor was recently approved in the European Union (EU) for the treatment of patients with advanced neuroendocrine tumors (NET) of pancreatic origin with progressive disease. The drug is already approved in the US for the indication. The approval was based...
11Sep2011 | vitalstocks | 0 comments | Continued(SCR) Simcere Drug Cleared in China
Recently, the State Food and Drug Administration (SFDA) of China delivered a boost to Simcere Pharmaceutical Group (SCR) by clearing its drug Iremod, for treating patients suffering from active rheumatoid arthritis (RA). Iremod, developed solely by Simcere, will be the first...
1Sep2011 | vitalstocks | 0 comments | Continued(ALL) Company News for August 30, 2011 – Corporate Summary
• Bank of America (NYSE:BAC) shares increased 8.12% to close at $8.39 after the bank disclosed it would be selling half of its holdings to China Construction Bank Corp in order to raise capital • Share prices of insurer The Allstate Corp. (NYSE:ALL) advanced 8.50%...
30Aug2011 | vitalstocks | 0 comments | Continued(ABC) AmerisourceBergen Analyst Reiterates Neutral on Shares
We recently reiterated our Neutral recommendation on AmerisourceBergen Corporation (ABC) with a target price of $40.00. Over the last several years, the company has been benefiting from the growth of the pharmaceutical industry in the US. We believe AmerisourceBergen should continue...
26Aug2011 | vitalstocks | 0 comments | Continued(WPI) Watson Pharmaceuticals Analyst Maintains Outperform on Shares
We continue to have an Outperform recommendation on Watson Pharmaceuticals, Inc. (WPI), with a target price of $79.00, following the release of second quarter 2011 results. Watson Pharma’s second quarter earnings of $1.01 per share (excluding special items) outpaced the Zacks...
26Aug2011 | vitalstocks | 0 comments | Continued(MYL) Mylan Analyst Reaffirms Shares at Neutral
We have maintained our Neutral recommendation on Mylan Inc. (MYL) with a target price of $19.00 following an appraisal of second quarter 2011 financial results. Mylan’s second quarter 2011 earnings (excluding special items) of 52 cents per share were above the Zacks Consensus...
25Aug2011 | vitalstocks | 0 comments | Continued(BK) Company News for August 15, 2011 – Corporate Summary
• Dillard’s Inc. (NYSE:DDS) posted strong second-quarter 2011 earnings of $0.30 per share, outpacing the Zacks Consensus Estimate of $0.19 per share and prior-year quarter earnings of $0.03 per share • J. C. Penney Company, Inc. (NYSE:JCP) posted second-quarter...
16Aug2011 | vitalstocks | 0 comments | Continued(ONXX) Onyx Analyst Downgrades Shares to Underperform
We recently downgraded our recommendation on Onyx Pharmaceuticals, Inc. (ONXX) to Underperform from Neutral. We note that Onyx Pharma’s second quarter 2011 loss of 56 cents was well below expectations, mainly due to lower revenues and higher operating expenses. Despite improved...
16Aug2011 | vitalstocks | 0 comments | Continued(AA) Stock Market News for August 16, 2011 – Market News
In what is being termed as the return of “Merger Monday”, an acquisition spree gave a boost to markets which posted its longest rally since early July. Additionally, positive economic news from Japan also brought joy to the markets and helped the Dow record its best three-day...
16Aug2011 | vitalstocks | 0 comments | Continued(VVUS) Vivus’ Loss Narrowed Due To Lower Spend
Vivus Inc. (VVUS) posted adjusted loss of 14 cents per share during the second quarter of fiscal 2011, in line with the Zacks Consensus Estimate. However, the loss was narrower than the year-ago loss of 27 cents per share. Lower operating expenses led to the narrower loss. The...
9Aug2011 | vitalstocks | 0 comments | Continued(BMY) Bristol-Myers Squibb Company Reports Solid Quarter
Bristol-Myers Squibb Company’s (BMY) second quarter 2011 earnings (excluding special items) of $0.56 per share surpassed the Zacks Consensus Estimate by $0.01and the year-ago earnings by $0.02. Higher revenues boosted earnings in the reported quarter. On a reported basis (including...
3Aug2011 | vitalstocks | 0 comments | Continued(BGC) Company News for August 3, 2011 – Corporate Summary
• Westlake Chemical Corporation (NYSE:WLK) posted Q2 EPS of $1.21, beating analysts’ estimates of $1.19 per share. Revenues rose 13% year-over-year to $925.0 million • Engineering company Foster Wheeler AG’s (NASDAQ:FWLT) shares rose 2.12% to close at $27.02...
3Aug2011 | vitalstocks | 0 comments | Continued(RDY) Dr. Reddy’s Laboratories Earns FDA Approval for Generic
Dr. Reddy’s Laboratories (RDY) delivered yet another positive momentum within a week, as the US Food and Drug Administration (FDA) approved fondaparinux sodium injection, the company’s bioequivalent generic version of Arixtra. The drug is currently marketed by GlaxoSmithKline...
14Jul2011 | vitalstocks | 0 comments | Continued(KCI) Kinetic Concepts Aquired by Apax Partners and Two Canadian Pension Funds
Private equity firm Apax Partners and two Canadian pension funds are set to acquire leading medical technology company Kinetic Concepts (KCI). The deal, including Kinetic’s outstanding debt, is valued at approximately $6.3 billion. As an independent global partnership,...
14Jul2011 | vitalstocks | 0 comments | Continued(NVS) Novartis Presents Afinitor Data
Recently, Novartis (NVS) presented data from a late-stage study (EXIST-1) of its cancer drug Afinitor (everolimus). The randomized, placebo-controlled, double-blind, multicenter study evaluated the safety and effectiveness of the drug compared to placebo for treating patients...
12Jul2011 | vitalstocks | 0 comments | Continued(ADP) Stock Market News for July 8, 2011 – Market News
On Thursday, positive jobs and retail reports lifted investor sentiment and subsequently boosted the benchmarks which edged closer to 2011 highs. Nonetheless, volumes remained tight as investors anxiously await crucial non-farm payroll data from the government. The Dow Jones...
8Jul2011 | vitalstocks | 0 comments | Continued(NVS) Novartis AG’s Afinitor Impresses Again
It seems Novartis AG’s (NVS) breast cancer drug, Afinitor (everolimus), is getting into a habit of delivering positive news. Right after the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended approval of Afinitor last week...
7Jul2011 | vitalstocks | 0 comments | Continued